Liver lesions show up on imaging as spots, masses, or areas that look different from the surrounding normal liver tissue, and their appearance varies dramatically depending on what they are. A fluid-filled cyst looks nothing like a solid tumor, and a benign blood-vessel tangle behaves differently under contrast dye than a cancerous growth. Radiologists rely on specific visual signatures on ultrasound, CT, and MRI to tell these apart, and in many cases the imaging pattern alone is enough to make a confident diagnosis without ever needing a biopsy.
How Common Are Incidental Liver Lesions
Many people first learn they have a liver lesion because imaging was done for something else entirely. These incidental findings are common enough that they have their own abbreviation in radiology circles. One large study of cancer patients found that about one in eight had small liver lesions spotted on CT, and roughly 80% of those lesions showed no growth over an average follow-up of about two years, meaning they were almost certainly benign.1PubMed. Prevalence and importance of small hepatic lesions found at CT in patients with cancer The anxiety these findings produce can lead to unnecessary invasive follow-up, which is why the imaging appearance matters so much: if a lesion looks textbook-benign, further workup may not be needed at all.2PubMed Central. WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver
Simple Cysts
Simple liver cysts are among the most frequently encountered lesions and among the easiest to identify. On ultrasound, they appear as completely dark (anechoic) round areas with sharp edges and a bright signal behind them, a feature caused by sound waves passing freely through fluid. On CT, they show up as well-defined dark spots that measure close to the density of water and do not light up at all when contrast dye is injected. MRI tells a similar story: the cyst stays dark on certain sequences and bright on others consistent with fluid, and again shows zero enhancement after contrast.3PubMed Central. Differentiating Cystic Liver Lesions: A Review of Imaging Modalities, Diagnosis and Management When a cyst checks all these boxes, the diagnosis is essentially locked in.
Complex cysts are a different story. These may have internal walls (septations), irregular borders, or areas of calcification. On contrast-enhanced ultrasound, worrisome complex cysts show enhancement along their walls or internal nodules during the early arterial phase, then become darker than the surrounding liver later on. That pattern raises the suspicion of a pre-malignant or malignant process and usually triggers further investigation.3PubMed Central. Differentiating Cystic Liver Lesions: A Review of Imaging Modalities, Diagnosis and Management
Hemangiomas
Hemangiomas are the most common solid benign liver tumor, essentially tangles of blood vessels that almost never cause symptoms. On a non-contrast CT scan, a hemangioma appears as a well-defined dark spot. The telltale behavior comes after contrast dye is given: bright enhancement starts at the edges of the lesion in a globular, nodular pattern, then slowly fills inward toward the center over the course of minutes.4PubMed Central. Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies Radiologists sometimes describe this as “peripheral nodular enhancement with centripetal fill-in,” and it is one of the most recognizable patterns in liver imaging. On MRI, hemangiomas are characteristically very bright on T2-weighted images, sometimes described as a “light bulb” appearance, which helps distinguish them from most malignant lesions.
Small hemangiomas can sometimes fill in so quickly that the slow-fill pattern is hard to catch, which is why the combination of CT and MRI features together usually clinches the diagnosis. In a healthy liver, a lesion that behaves this way on imaging rarely needs further workup.
Focal Nodular Hyperplasia
Focal nodular hyperplasia (FNH) is a benign growth found most often in young women. It develops in otherwise normal liver tissue and is thought to arise from a localized vascular abnormality that causes the liver cells around it to overgrow. On imaging, its hallmark is a central scar: a star-shaped or spoke-wheel area in the middle of the lesion that stands out on MRI and sometimes on CT. FNH enhances brightly and uniformly in the arterial phase of contrast imaging, then fades to blend in with normal liver in later phases. CT, MRI, and contrast-enhanced ultrasound can all often make the diagnosis accurately.5Radiographics. Focal Nodular Hyperplasia and Focal Nodular Hyperplasia-like Lesions Because FNH carries virtually no risk of bleeding or turning cancerous, confirmed cases typically just get monitored or left alone.
Hepatocellular Adenomas
Hepatocellular adenomas are rarer and more clinically significant than FNH. They are linked to oral contraceptive use and anabolic steroid exposure, and unlike FNH, they carry a real risk of bleeding or malignant transformation, particularly when larger. MRI is the key tool for characterizing adenomas because different molecular subtypes produce different imaging patterns. The most common subtype (HNF1-alpha mutated) tends to contain fat, making it appear signal-bright on certain MRI sequences, while inflammatory adenomas show signs of dilated blood-filled spaces and distinctive patterns of persistent enhancement.6PubMed. New MRI features improve subtype classification of hepatocellular adenoma
Subtyping matters because the risk profile differs. In that same study, no malignant transformation was observed in adenomas smaller than about 5 cm, and no bleeding occurred in those smaller than about 4 cm.6PubMed. New MRI features improve subtype classification of hepatocellular adenoma Larger adenomas, or those with beta-catenin mutations (which are harder to classify on MRI), are the ones that tend to get resected. Some adenomas that have been heavily distorted by internal bleeding or tissue death can be difficult to classify by imaging at all, which is when biopsy becomes necessary.
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and tends to arise in livers already damaged by cirrhosis, chronic hepatitis B, or fatty liver disease. Its imaging fingerprint relies on how the tumor uses blood. HCC gets most of its blood supply from hepatic arteries rather than the portal vein, so during the arterial phase of a contrast-enhanced scan, HCC lights up brightly. Then, in the portal venous or later phases, the tumor becomes darker than the surrounding liver, a phenomenon called “washout.” This combination of arterial hyperenhancement followed by washout is one of the most reliable imaging indicators of HCC.7PubMed Central. The Washout of Hepatocellular Carcinoma at Portal Venous Phase vs. Equilibrium Phase: Radiological and Clinicopathological Implication 8PubMed. Quantitatively defining washout in hepatocellular carcinoma
Other features that raise suspicion include a visible capsule around the lesion (an enhancing rim seen on delayed imaging), growth into a portal vein branch, and internal mosaic-like heterogeneity in larger tumors. In patients with known cirrhosis, imaging alone is considered diagnostic for HCC when the classic pattern is present, and a biopsy is not always required. This is unusual in oncology, where tissue sampling is usually mandatory before treatment.
Liver Metastases and Cholangiocarcinoma
The liver is one of the most common sites for cancer to spread, so liver metastases are among the most frequently encountered malignant liver lesions. Their appearance varies depending on the primary cancer. Metastases from colon cancer, for example, tend to show up as multiple round lesions with rim enhancement after contrast, sometimes with a dark center where tissue has died. Metastases from highly vascular tumors like kidney cancer or thyroid cancer can mimic hemangiomas by enhancing brightly in the arterial phase, which is why clinical context and the patient’s cancer history matter enormously in interpretation.
Cholangiocarcinoma, a cancer of the bile ducts within the liver, looks quite different from HCC. The intrahepatic form tends to appear as a large, irregular mass that enhances around the edges early but fills in slowly and incompletely. A characteristic feature is capsular retraction, where the liver surface appears pulled inward toward the tumor. This retraction reflects the tumor’s dense fibrous tissue contracting as it grows.9PubMed Central. Hepatic capsular retraction: spectrum of diagnosis at MRI That pulling-in sign can also appear with other conditions, but when seen alongside a large mass with delayed enhancement in a non-cirrhotic liver, cholangiocarcinoma rises to the top of the list.
How Radiologists Score Suspicious Lesions
In patients at risk for HCC (those with cirrhosis or chronic hepatitis), radiologists do not just eyeball the images. They use a standardized system called LI-RADS (Liver Imaging Reporting and Data System) that assigns each lesion a category from LR-1 (definitely benign) to LR-5 (definitely HCC). The system looks at specific features, mainly arterial hyperenhancement, washout, capsule appearance, and size, and combines them to produce a score. A validation study found that among observations rated LR-5 or higher, around 83 to 95% turned out to be HCC, while essentially 0% of LR-1 lesions were cancerous.10PubMed. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma The system is designed to be highly specific: it would rather err on the side of calling something indeterminate than incorrectly labeling a benign lesion as cancer.
The middle categories (LR-3 and LR-4) represent the gray zone. LR-3 lesions have roughly an 11 to 27% chance of being HCC depending on the reader, while LR-4 lesions carry a 50 to 76% chance.10PubMed. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma These lesions typically get short-interval follow-up imaging or biopsy rather than immediate treatment.
Pseudolesions That Look Like Masses but Are Not
Not everything that looks like a lesion on imaging is actually a distinct mass. Focal fatty deposits, where fat accumulates in a localized area of the liver, can mimic a tumor on ultrasound or even on standard CT. Fortunately, MRI handles these confidently. On a specific pair of MRI sequences called in-phase and out-of-phase imaging, fat-containing areas lose signal on the out-of-phase images compared to in-phase, a pattern that does not occur with true tumors. Focal fat deposits also tend to have wedge-shaped or geographic borders, do not push on nearby blood vessels, and do not restrict water diffusion on diffusion-weighted imaging.11PubMed Central. Fatty liver deposition and sparing: a pictorial review The mirror image, focal fatty sparing, where a patch of normal liver stands out against a background of diffuse fat, can also be mistaken for a mass. The same MRI technique resolves the question.
Transient perfusion differences, where a segment of liver enhances differently because of a nearby vein or arteriovenous shunt, are another common pseudolesion. These typically appear wedge-shaped, follow vascular territories, and disappear on delayed phases. Recognizing these artifacts prevents patients from being subjected to biopsies for what is essentially a blood-flow quirk.
Liver Abscesses
Liver abscesses look different from tumors but can overlap enough to cause confusion. The classic finding on contrast-enhanced CT is the “double target sign”: a dark central cavity of liquefied infected material, surrounded by a bright enhancing wall, surrounded again by a dark halo of swollen tissue.12PubMed. Dynamic CT features of hepatic abscesses Amebic abscesses, caused by a parasitic infection, have their own variations: some show a smooth-walled rim with a peripheral low-density halo creating a similar double-target appearance.13PubMed Central. Hepatobiliary CT of amebic liver abscess: different morphological types with different clinical features Clinical history helps enormously here, since a patient with fever, elevated white blood cells, and recent travel to an endemic area is a very different scenario from an asymptomatic patient with an incidental mass on imaging.
Diffusion-Weighted MRI as a Tiebreaker
When a lesion does not fit neatly into a diagnostic box, diffusion-weighted imaging (DWI) on MRI can help. This technique measures how freely water molecules move within tissue. Malignant tumors, with their tightly packed cells, restrict water movement and appear bright on DWI. Benign lesions like cysts and hemangiomas, where water moves freely, tend to be dark. The quantitative measurement of this restriction is called the apparent diffusion coefficient (ADC), and it consistently differs between benign and malignant liver lesions.
Multiple studies have confirmed this separation. One found that benign lesions had a mean ADC roughly 50% higher than malignant lesions, and that using a specific cutoff value could differentiate the two with about 92% sensitivity and 80% specificity.14PubMed Central. Evaluation of ADC ratio on liver MRI diffusion to discriminate benign versus malignant solid liver lesions Another study reported even stronger performance, with sensitivity above 97% and specificity above 98%.15Egyptian Liver Journal. The diagnostic value of diffusion-weighted imaging in differentiating benign from malignant hepatic lesions The exact cutoff values vary between studies and institutions because of differences in MRI equipment and technique, but the direction is always the same: lower ADC values point toward malignancy. DWI is not a standalone diagnostic tool, but it is a powerful tiebreaker when added to standard contrast-enhanced imaging.
Liver-Specific Contrast Agents
Standard CT and MRI contrast agents flow through blood vessels and wash out relatively quickly. Liver-specific MRI contrast agents, particularly gadoxetic acid, behave differently. After an initial vascular phase that works like regular contrast, the agent gets taken up by functioning liver cells and excreted into bile. This creates a delayed “hepatobiliary phase” image, typically taken about 20 minutes after injection, where normal liver tissue appears bright because it has absorbed the agent, and most lesions that lack functioning liver cells appear dark by comparison.16PubMed. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver
This extra phase is especially useful for detecting small lesions that might be missed on regular contrast imaging and for characterizing ambiguous lesions. FNH, for instance, typically retains the agent and appears bright on hepatobiliary phase images because it contains functioning liver cells, while most malignant lesions do not retain it and appear dark. However, the reality is more nuanced than a simple bright-versus-dark dichotomy. Various lesions can show different patterns of enhancement or retention, and radiologists are learning that examining the pattern, not just whether it enhances, gives the most diagnostic information.17PubMed Central. Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI Overall, detection and characterization of focal liver lesions appears to be improved with hepatobiliary agents compared to standard MRI contrast or contrast-enhanced CT.18PubMed. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications
What Treated Lesions Look Like
After treatment for liver cancer, imaging takes on a different role: tracking whether the therapy worked and watching for recurrence. The expected appearance depends entirely on what treatment was used. After radiofrequency ablation, the treated zone should appear as a non-enhancing area (no contrast uptake) that is slightly larger than the original tumor, because ablation intentionally destroys a margin of normal tissue around the cancer. Any new enhancement within or at the edges of the ablation zone on follow-up raises concern for residual or recurrent tumor.19PubMed. Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation
After chemoembolization, which delivers chemotherapy and blocks the tumor’s blood supply, the appearance is more complex. The material used (often mixed with an oil called lipiodol) appears very bright on non-contrast CT, which can actually make it harder to see whether viable tumor remains underneath. MRI and contrast-enhanced ultrasound can see through this artifact better than CT alone and are often used as complementary tools.20PubMed Central. Imaging appearance of treated hepatocellular carcinoma 19PubMed. Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation The general rule for post-treatment imaging is straightforward: dead tumor does not enhance; anything that lights up with contrast in the treatment zone warrants attention.
Pediatric Liver Masses
Children are not just small adults when it comes to liver imaging. The spectrum of liver masses in children is completely different from what appears in adult livers. In children from birth to six years, the most common liver masses include hepatoblastoma (the most common primary liver malignancy in this age group), infantile hemangioma (a benign vascular tumor with a distinctive imaging appearance), and mesenchymal hamartoma, a rare developmental lesion.21PubMed Central. Imaging insights into pediatric liver masses: A comprehensive minireview for hepatology practice Hepatoblastoma tends to appear as a large, heterogeneous mass with areas of calcification. Infantile hemangiomas typically present in the first few months of life and often show intense early enhancement that fills in over time. The clinical approach in pediatric cases relies heavily on age, blood markers (particularly alpha-fetoprotein for hepatoblastoma), and imaging patterns together, since biopsy is more challenging and riskier in small children.
Fusion Imaging for Lesions That Hide on Ultrasound
Some liver lesions are clearly visible on CT or MRI but nearly invisible on ultrasound. This creates a practical problem: ultrasound is the preferred tool for guiding biopsies and certain treatments like thermal ablation because it is real-time and does not involve radiation. Fusion imaging solves this by electronically overlaying a previously obtained CT or MRI scan onto the live ultrasound image, so the radiologist can see both simultaneously and use the CT/MRI roadmap to find the lesion in real time.22PubMed Central. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention
This technology has expanded the range of lesions that can be treated with ultrasound-guided ablation. One study of liver metastases that were poorly visible on conventional ultrasound found that fusion imaging improved conspicuity enough to allow successful microwave ablation in about 83% of cases that would otherwise have been untreatable by this route.23PubMed. Percutaneous Thermal Ablation with Ultrasound Guidance. Fusion Imaging Guidance to Improve Conspicuity of Liver Metastasis Emerging approaches go further: super-resolution contrast-enhanced ultrasound can map the tiny blood vessels within a lesion at a level of detail previously only possible with advanced MRI or pathology, potentially adding another layer of characterization to guide decisions about what a lesion is and how to treat it.24Portal Hypertension & Cirrhosis. Sono‐Vasomics With Super‐Resolution Contrast‐Enhanced Ultrasound (SR‐CEUS) for Characterization of Focal Liver Lesions: A Case Report
Artificial Intelligence in Liver Imaging
AI and machine learning tools are being developed to assist radiologists in interpreting liver imaging, not replace them. These systems can be trained on thousands of images to recognize patterns associated with specific lesion types, and research has shown potential for AI to help characterize focal liver lesions, stage liver fibrosis, detect portal hypertension, and even predict how aggressively a malignant tumor will behave.25PubMed Central. Radiomics and Deep Learning: Hepatic Applications The practical appeal is speed and consistency: an AI system does not get fatigued at the end of a long reading session and may catch subtle features a human eye might miss. That said, most of these tools remain in the research phase rather than routine clinical use, and they work best as a second set of eyes rather than as an independent decision-maker.